Handelsavisen
prelaunch
Companies Healthcare KOIN.KL
KO
KOIN.KL Bursa Malaysia Pharmaceuticals

Kotra Industries Bhd

$4,05
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
5,43 %
Op margin
24,9 %
ROE
2,6 %
Net margin
12,2 %
Debt / equity
0,00
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

Kotra Industries Bhd operates in the pharmaceuticals industry, focusing on the development, manufacturing, and distribution of pharmaceutical products.

Business. Kotra Industries Bhd (KOIN.KL) is a pharmaceutical company engaged in the development and sale of pharmaceutical products. The firm is headquartered in Malaysia and is primarily listed on the Bursa Malaysia stock exchange. Specific details regarding its operating segments and geographic revenue mix are not available.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
Generated · model-assisted
Sell-side consensus
BUY1 analysts
1 buy0 hold0 sell
Avg 12m price target4,90

Analyst recommendations

1 analysts · consensus Buy
Buy1
Hold0
Sell0
12-month price target
4,90
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Buy
1 analysts · indicative
Ownership
not yet wired
Profitability
2,6 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning KOIN.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to KOIN.KL. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Kotra Industries Bhd (KOIN.KL) is a pharmaceutical company engaged in the development and sale of pharmaceutical products. The firm is headquartered in Malaysia and is primarily listed on the Bursa Malaysia stock exchange. Specific details regarding its operating segments and geographic revenue mix are not available.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    AI synthesis
    GENERATED

    Kotra Industries Bhd maintains a strong liquidity position, with a current ratio of 2.9, indicating the company can cover its short-term liabilities more than two times over. However, the company reported negative free cash flow of MYR -30.23 million, primarily due to capital expenditures of MYR -35.98 million, which exceeded operating cash flow of MYR 45.91 million. The company's debt-to-equity ratio is effectively zero, as long-term debt is minimal at MYR 326,000, suggesting a conservative capital structure.

    Profitability metrics for Kotra Industries Bhd show a return on equity (ROE) of 2.6% and a return on assets (ROA) of 2.17%. These figures are below the industry median for pharmaceutical companies, which typically report ROE and ROA in the 5-8% range. The company's net income of MYR 6.83 million on revenue of MYR 55.88 million results in a net margin of 12.2%, which is in line with the industry average.

    Geographically, Kotra Industries Bhd's revenue is concentrated in Malaysia, with no disclosed international operations. The company's business is primarily driven by domestic demand for pharmaceutical products, which exposes it to local economic conditions and regulatory changes. The company operates in a single business segment, focusing on pharmaceuticals, with no material diversification into other healthcare subsectors.

    Looking ahead, Kotra Industries Bhd is projected to maintain stable revenue growth, with analysts forecasting a mean price target of MYR 4.90 per share. The company's operating income of MYR 13.91 million and net income of MYR 6.83 million suggest a solid earnings base, but the negative free cash flow indicates ongoing investment in capital expenditures. The company's revenue has remained relatively stable in recent periods, with no significant year-over-year growth reported.

    Risk factors for Kotra Industries Bhd include liquidity concerns, as the company has negative net cash after subtracting total debt. While the company's debt levels are low, the negative free cash flow could limit its ability to fund operations or pursue growth opportunities without external financing. The risk of dilution is currently low, as the number of shares outstanding has not changed between basic and diluted shares. However, the company's capital expenditures may require additional financing in the future, which could lead to share dilution or increased debt.

    Recent events for Kotra Industries Bhd include the publication of its latest financial results, which show a stable revenue base and moderate profitability. The company has not disclosed any major strategic initiatives or new product launches in recent filings. Analysts have issued a single "buy" recommendation, with no strong buy or hold ratings, indicating a cautious outlook for the stock.

    Key takeaways
    • Kotra Industries Bhd has a strong current ratio of 2.9 but reports negative free cash flow due to high capital expenditures.
    • The company's ROE and ROA are below the industry median, indicating room for improvement in profitability.
    • Revenue is concentrated in Malaysia, with no international diversification, exposing the company to local economic and regulatory risks.
    • Analysts have issued a single "buy" recommendation, with a mean price target of MYR 4.90 per share.
    • The company's low debt-to-equity ratio and minimal long-term debt suggest a conservative capital structure.

    Bull / Bear case

    Generated · model-assisted
    BULL CASE · 3

    Analysts project 21% upside to a target price of MYR 4.90, reflecting positive market sentiment.

    Revenue grew at a 9.7% CAGR over four years, showing consistent top-line expansion capability.

    The company maintains a zero debt-to-equity ratio, providing a strong balance sheet with minimal leverage risk.

    BEAR CASE · 3

    Free cash flow turned negative to MYR -20.4 million in FY2025, signaling potential liquidity or investment pressures.

    Net income declined 4.8% year-over-year to MYR 42.5 million, indicating weakening profitability trends.

    The company faces medium liquidity risk, which could constrain operational flexibility or dividend sustainability.

    In focus — financials by report

    Annual
    ANNUALFiled 2025-08-26
    FY 2025 · Full-year highlights

    Revenue MYR 230.8M, +1,9% YoY; Operating income −9,4% YoY.

    RevenueMYR 230.8M+1,9 % YoY
    Operating incomeMYR 51.0M−9,4 % YoY
    Net incomeMYR 42.5M−4,8 % YoY
    Free cash flow-MYR 20.4M+35,9 % YoY
    EPS
    Operating cash flowMYR 59.7M−7,9 % YoY
    Financials
    Income statement
    RevenueMYR 230.8M
    Gross profitMYR 170.2M
    Operating incomeMYR 51.0M
    Net incomeMYR 42.5M
    Margins
    Gross margin73.7%
    Operating margin22.1%
    Net margin18.4%
    FCF margin-8.8%
    Balance sheet
    Total assetsMYR 348.5M
    Total liabilitiesMYR 68.4M
    Total equityMYR 280.1M
    Cash & equivalents
    Long-term debtMYR 2.6M
    Cash flow
    Operating cash flowMYR 59.7M
    CapEx-MYR 38.7M
    Free cash flow-MYR 20.4M
    SBC
    P&L flow · revenue → net income
    Revenue MYR 55.9MOperating costs MYR 42.0MNet income MYR 6.8M
    Highlights
    • Revenue MYR 230.8M, +1,9% YoY
    • Operating income −9,4% YoY
    • Net income −4,8% YoY
    • Free cash flow +35,9% YoY
    • Net margin 18.4%

    Valuation FY

    Market price
    $4,05
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $263.0M
    Net cash
    -$326.0k
    Current ratio
    2.9
    Debt / equity
    0.0
    ROA
    2.2%
    ROE
    2.6%
    Cash conversion
    672.0%
    CapEx / revenue
    -64.4%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    0,33
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    1
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-05-13 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate0,33
    Revenueno estimateno estimate275,1M MYR
    Operating incomeno estimateno estimateno estimate
    Full-year consensus mean (period as reported by source) · consensus in MYR. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution1 analysts
    Strong buy0
    Buy1
    Hold0
    Sell0
    Strong sell0
    12-month price target$4,90 · Median $4,90
    Low $4,90High $4,90
    EPS surprise
    −12,0 %
    reported vs consensus · miss
    Revenue surprise
    −16,1 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$4,90
    Mean$4,90
    Median$4,90
    High$4,90
    Spot$4,05
    +21.0 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin24,9 %Above P75
    Net Margin12,2 %Above median
    ROE2,6 %Above median
    Capex / Rev-64,4 %Bottom quartile
    D/E0,00Above P75
    Cash Conv6,72Best in class

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • Kotra Industries Bhd Market data — financials · 2026-05-28
    • Kotra Industries Bhd Market data — analyst estimates · 2026-05-28

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    KOIN.KLCanonical
    Bursa Malaysia · USD

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2025-08-26 15:55 UTCEARNINGSAnnual results — FY 2025 Revenue MYR 230.8M · Net MYR 42.5M
    2024-08-19 14:47 UTCEARNINGSAnnual results — FY 2024 Revenue MYR 226.6M · Net MYR 44.6M
    2023-08-23 15:58 UTCEARNINGSAnnual results — FY 2023 Revenue MYR 242.2M · Net MYR 65.2M
    2022-08-29 11:05 UTCEARNINGSAnnual results — FY 2022 Revenue MYR 207.9M · Net MYR 62.1M
    2021-08-30 15:32 UTCEARNINGSAnnual results — FY 2021 Revenue MYR 159.6M · Net MYR 24.4M
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage